Displaying 261 - 280 of 853
| Active Ingredient | EZETIMIBE |
| Therapeutic Class | CHOLESTEROL ABSORPTION INHIBITORS |
| Indications | An adjunct to dietary measures and statin treatment.Reduction of total cholesterol, low-density lipoprotein (LDL)-cholesterol, and apolipoprotein B in the management of hyperlipidaemias. |
| Caution | Headache, abdominal pain, and diarrhoea. Contraindicated in patients with active liver disease or unexplained, persistent increases in serum aminotransferase (transaminase) concentrations. |
| Dose Range | 10mg once daily . Must be used in combination with a statin. |
| Drug Interactions | |
| Pregnancy | Use during pregnancy only if potential benefit to the mother outweighs the possi More ... |
| Breast Feeding |
| Active Ingredient | FENOFIBRATE |
| Therapeutic Class | FIBRIC ACID DERIVATIVES |
| Indications |
Used to reduce low-density lipoprotein (LDL)-cholesterol, total cholesterol, triglycerides, and apolipop rotein B, and to increase high-density lipoprotein (HDL)-cholesterol, in the management of Hy More ... |
| Caution | Liver function test should be carried out every 3 months.Serious muscle toxicity, including myopathy and rhabdomyolysis, has been reported in patients receiving fibric acid derivatives. Risk appears t More ... |
| Dose Range |
Adult: 67 mg three times daily or 200 mg once daily . Pediatric (4-15 years): 1 cap sule/20mg daily . |
| Drug Interactions | |
| Pregnancy | Fenofibrate is not recommended during pregnancy. |
| Breast Feeding | Fenofibrate is not recommended for lactating women. |
| Active Ingredient | GEMFIBROZIL |
| Therapeutic Class | FIBRIC ACID DERIVATIVES |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | ATORVASTATIN |
| Therapeutic Class | HMG-CoA REDUCTASE INHIBITORS |
| Indications |
Effective in the treatment of hyper-cholesterolemia and hypertrigly ceridemia. |
| Caution | Headache, diarrhoea, flatulence and mild elevations in liverenzymes. The risk of myopathy and/or rhabdomyolysis is increased when atorvastatin is taken concomitantly with cyclosporine, gemfibrozil, More ... |
| Dose Range |
Adult: Initial dose 10-20mg once daily. The dose may be adjusted at intervals of at least 4 weeks up to a maximum of 80 mg daily . See BDS supply protocols pg. 6. |
| Drug Interactions | |
| Pregnancy | Statins should be avoided in pregnancy (discontinue 3 months before attempting t More ... |
| Breast Feeding | Avoid use of atorvastatin in lactating women. |
| Active Ingredient | ROSUVASTATIN |
| Therapeutic Class | HMG-CoA REDUCTASE INHIBITORS |
| Indications | Primary hypercholesterolaemia (type IIa including heterozygous familial hypercholesterolaemia)’ mixed dyslipidaemia (type Iib), or homozygous familial hypercholesterolaemia in patients who have n More ... |
| Caution | Headache, asthenia, upper respiratory infections, gastrointestinal symptoms, and myalgia have been reported; myopathy has occurred rarely . |
| Dose Range | Adult: 5-20mg once daily . Doses may be titrated to 40mg per day in those who do not meet their lipid lowering goals on 20mg per day. Doses to be increased at intervals of at least 4 weeks. See BDS supply protocols pg. 6. |
| Drug Interactions | |
| Pregnancy | Statins should be avoided in pregnancy (discontinue 3 months before attempting t More ... |
| Breast Feeding | Avoid use of rosuvastatin in lactating women. |
| Active Ingredient | AMLODIPINE | ATORVASTATIN |
| Therapeutic Class | ANTILIPEMIC MISCELLANEOUS |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | EZETIMIBE | SIMVASTATIN |
| Therapeutic Class | ANTILIPEMIC MISCELLANEOUS |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | HYPOTENSIVE AGENTS |
| Therapeutic Class | HYPOTENSIVE AGENTS |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | METHYLDOPA |
| Therapeutic Class | CENTRAL ALPHA ANTAGONIST |
| Indications | Hypertension. |
| Caution | Rarely : Positive response to direct Coombs tests. Haemolytic anaemia, leukopenia, thrombocytopenia, hepatitis, gynaecomastia and lactation. Safe in asthmatics and pregnancy.Dose dependen More ... |
| Dose Range |
Adult: Initial dose: 250mg 2-3 times daily for 2 days, adjusted every 2 days to a maximum of 3g daily. Maintenance dose: 500mg-2g in 2- 4 divided doses. Pediatric: 10mg/kg in 2-4 divided doses initially , to a maximum of 65mg/kg or 3g whichever is less. |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | HYDRALLAZINE |
| Therapeutic Class | DIRECT VASODILATOR |
| Indications |
Moderate to severe hypertension. As a vasodilator decreasing afterload in intractable heart failure. To be used with a diuretic and beta blocker. |
| Caution | May cause angina in predisposed patients. Reversible SLE type syndrome with prolonged use of more than 200mg/day. Must be used with caution in patients on MAOI's or tricyclics. Severe headache, More ... |
| Dose Range |
Oral: 50-100mg daily in 2 divided doses. Inj: 5-10mg i.m. or i.v. by slow titration over 20-30 minutes or 200-300mcg/min by slow iv infusion. |
| Drug Interactions | |
| Pregnancy | Manufacturer advises that hydralazine should not be used before third trimester More ... |
| Breast Feeding | Use with caution as hydralazine is distributed into breastmilk but is not known More ... |
| Active Ingredient | MINOXIDIL |
| Therapeutic Class | DIRECT VASODILATOR |
| Indications | Severe hypertension unresponsive to standard therapy. Must be given with a beta blocker, and with a diuretic. |
| Caution | Potent vasodilator. May cause hirsutism and considerable oedema due to salt and water retention. |
| Dose Range |
Initially 5mg daily (elderly : 2.5mg) as a single or in divided doses gradually increased at 3 day intervals to 50mg daily. Maximum 100mg daily . |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | AMLODIPINE | CHLORTHALIDONE |
| Therapeutic Class | HYPOTENSIVE AGENTS, MISCELLANEOUS |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | AMLODIPINE | INDAPAMIDE |
| Therapeutic Class | HYPOTENSIVE AGENTS, MISCELLANEOUS |
| Indications | Hypertension in patients stabilised on the individual components. |
| Caution | As for amlodipine, indapamide. |
| Dose Range | In hypertension, the usual dose is 1.5mg\5mg once daily, increasing if necessary to 1.5mg\10mg once daily. |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | AMLODIPINE | TELMISARTAN |
| Therapeutic Class | HYPOTENSIVE AGENTS, MISCELLANEOUS |
| Indications | Treatment of mild to moderate hypertension. |
| Caution | Peripheral edema, dizziness and back pain. Edema (other than peripheral edema), hypotension, and syncope were reported, in a study which evaluated the concomitant use of Telmisartan and Amlodipine More ... |
| Dose Range | In hypertension the usual initial dose is 5 mg/80mg once daily, increased, if necessary, to 10mg/80mg once daily. |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | AMLODIPINE | VALSARTAN |
| Therapeutic Class | HYPOTENSIVE AGENTS, MISCELLANEOUS |
| Indications | Hypertension in patients stabilised on the individual components. |
| Caution | As for amlodipine, valsartan. |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | RILMENIDINE |
| Therapeutic Class | HYPOTENSIVE AGENTS, MISCELLANEOUS |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | ASPIRIN | DIPYRIDAMOLE |
| Therapeutic Class | VASODILATING AGENTS |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | BETAHISTINE |
| Therapeutic Class | VASODILATING AGENTS |
| Indications | Vertigo, tinnitus and hearing loss associated with Mé•nière'sdisease. |
| Caution | Gastro-intestinal disturbances; headache; pruritus; rashes. Betahistine should be given with care to patients with asthma, peptic ulcer disease or a history pepticulcer disease. |
| Dose Range | Initially 16mg 3 times a day, maintenance 24-48mg daily. Dose preferably taken with food. |
| Drug Interactions | |
| Pregnancy | Avoid unless clearly necessary. |
| Breast Feeding | Use only if potential benefit outweighs risk. |
| Active Ingredient | VASODILATING AGENTS |
| Therapeutic Class | VASODILATING AGENTS |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | GLYCERYL TRINITRATE |
| Therapeutic Class | NITRATES AND NITRITES |
| Indications | Used in treatment of angina at the onset of the attack, and in some cases for prophylaxis. |
| Caution | Over dosage:- palpitations, dizziness, blurred vision, headache, flushing followed by pallor. Postural hypotension, bradycardia, lightheadedness, reflux esophagus, contact dermatitis. |
| Dose Range |
Acute angina treatment: Sublingual Tablets (0.15 -0.6mg) or spray (0.4mg) may be repeated every 5 minutes until relief occurs; or 3 doses have been taken. To be taken under the tongue. Patients are tobe dispensed one full bottle of tablets every 2- |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |